Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
OhioHealth and Fairfield Medical Center Terminate Merger Plans
OhioHealth and Fairfield Medical Center have officially terminated their proposed merger plans, a development that alters the landscape of healthcare provider news in Ohio. The initial announcement of the acquisition proposal was made last November.
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
Cardiovascular drug developer Kardigan is gearing up for an IPO on the Nasdaq Global Market to finance the late-stage development of its pipeline, including danicamtiv for genetic dilated cardiomyopathy. This move signals a potential uptick in biotech IPOs as the market becomes more discerning.
Top Biotech Penny Stocks to Watch in 2026: A Strategic Outlook
Identifying promising biotech penny stocks under $1 for 2026 requires a deep dive into pipeline potential and market dynamics. This article highlights key companies poised for significant growth.
Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus
Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Structured plan for FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
The US FDA has approved MannKind's Afrezza inhaled insulin for pediatric patients aged 6 and older diagnosed with Type 1 or Type 2 diabetes. This approval marks a significant expansion for the inhaled insulin.
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Structured plan for Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer
The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.
Eli Lilly's 340B Data Mandate: A New Tactic in Pharma's Discount Program Battle
Eli Lilly has issued a five-day ultimatum to over 1,000 hospitals, requiring them to submit claims data or risk losing access to 340B drug discounts. This move signals a significant escalation in the ongoing conflict between pharmaceutical manufacturers and healthcare providers over the controversial program.
Eli Lilly's Retatrutide Success Amidst Regulatory Shifts: A Strategic Analysis
Eli Lilly's triple agonist, retatrutide, has achieved a significant Phase 3 win, demonstrating substantial weight loss. This success occurs against a backdrop of notable regulatory changes, impacting the pharmaceutical landscape.
Trump's Executive Order on Childhood Vaccine Schedules: Impact on Pharmaceutical Companies
President Trump has signed an executive order initiating an overhaul of the childhood vaccine schedule, signaling potential shifts in public health policy. This move could have significant implications for pharmaceutical companies involved in vaccine development and manufacturing.
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.
ASCO 2026: Key Takeaways on Cancer Care Barriers and New Treatments
The ASCO 2026 meeting highlighted critical barriers to effective cancer care and showcased promising new treatment modalities. Key takeaways offer insights into the evolving landscape of oncology drug development and patient access.
CEPI Funds Three Ebola Vaccine Candidates to Accelerate Outbreak Response
A global coalition, led by CEPI, has allocated $62 million to fast-track the development of three experimental Ebola vaccines. This significant investment aims to expedite the availability of crucial tools for combating future Ebola outbreaks.
DCAT Week 2024: Strategic Imperatives for Pharma BD and Investors
DCAT Week 2024 convened leaders across the pharmaceutical manufacturing value chain. This article distills critical insights for business development teams and investors, focusing on regulatory shifts, supply chain resilience, and strategic partnership opportunities.
White House Taps Amazon, GoodRx to Expand TrumpRx Generic Drug Access
The White House has partnered with Amazon Pharmacy and GoodRx to significantly expand TrumpRx.gov, integrating discounts for hundreds of generic drugs to enhance patient access and affordability.
FDA Leadership Vacuum: Navigating Uncertainty for Pharmaceutical Business Development
Recent leadership changes at the FDA have created a vacuum, potentially impacting regulatory timelines and strategic decision-making for pharmaceutical companies. This analysis explores the implications for business development, regulatory affairs, and investment.
Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer
Roche has secured an expanded approval for Alecensa in Japan, broadening its therapeutic reach for patients with ALK-positive non-small cell lung cancer. This development underscores Roche's commitment to advancing targeted therapies in oncology.
Supreme Court Upholds Medicare Drug Price Negotiation: Implications for Pharma
The Supreme Court has declined to hear appeals from several pharmaceutical companies challenging the Medicare drug price negotiation program. This decision allows the program to move forward, impacting future drug pricing strategies and market access for pharmaceutical companies.